BA
ABBV icon

Boston Advisors’s AbbVie ABBV Stock Holding History

Boston Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$6.25M Sell
82,489
-209
-0.3% -$14.3K 0.33% 84
2019
Q2 		$6.01M Sell
82,698
-6,506
-7% -$511K 0.32% 82
2019
Q1 		$7.19M Sell
89,204
-60,077
-40% -$4.91M 0.37% 68
2018
Q4 		$13.8M Sell
149,281
-5,363
-3% -$472K 0.8% 20
2018
Q3 		$14.6M Sell
154,644
-4,115
-3% -$390K 0.63% 20
2018
Q2 		$14.7M Sell
158,759
-454,724
-74% -$44.4M 0.37% 72
2018
Q1 		$58.1M Buy
613,483
+153,343
+33% +$16.8M 1.49% 9
2017
Q4 		$44.5M Buy
460,140
+300,954
+189% +$28.4M 0.96% 15
2017
Q3 		$14.1M Sell
159,186
-3,814
-2% -$290K 0.32% 96
2017
Q2 		$11.8M Buy
163,000
+64,589
+66% +$4.34M 0.27% 114
2017
Q1 		$6.41M Sell
98,411
-143,903
-59% -$9.05M 0.15% 178
2016
Q4 		$15.2M Sell
242,314
-281,040
-54% -$17.2M 0.36% 82
2016
Q3 		$33M Buy
523,354
+419,878
+406% +$27.2M 0.82% 23
2016
Q2 		$6.41M Sell
103,476
-632,258
-86% -$38.5M 0.16% 166
2016
Q1 		$42M Buy
735,734
+640,549
+673% +$35.7M 1.03% 15
2015
Q4 		$5.64M Sell
95,185
-32,518
-25% -$1.87M 0.13% 200
2015
Q3 		$6.95M Sell
127,703
-7,882
-6% -$513K 0.26% 120
2015
Q2 		$9.11M Buy
135,585
+44,795
+49% +$2.92M 0.38% 86
2015
Q1 		$5.32M Sell
90,790
-17,272
-16% -$1.04M 0.21% 144
2014
Q4 		$7.07M Buy
108,062
+23,348
+28% +$1.47M 0.3% 99
2014
Q3 		$4.89M Buy
84,714
+215
+0.3% +$11.9K 0.21% 133
2014
Q2 		$4.77M Sell
84,499
-1,260
-1% -$66.1K 0.2% 138
2014
Q1 		$4.41M Sell
85,759
-23,679
-22% -$1.2M 0.2% 136
2013
Q4 		$5.78M Sell
109,438
-203,933
-65% -$10M 0.28% 103
2013
Q3 		$14M Sell
313,371
-136,861
-30% -$6.07M 0.74% 42
2013
Q2 		$18.6M Buy
+450,232
New +$19.7M 0.9% 33

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Boston Advisors's ABBV Position: Q3 2019 in Review

Boston Advisors reduced its AbbVie (ABBV) stake by 0.25% in Q3 2019, selling an estimated $14.3K and leaving 82,489 shares worth $6.25M. The position accounts for 0.33% of the portfolio, ranked #84.

Boston Advisors first reported a position in ABBV in Q2 2013 and has held it in 26 quarters since. The position peaked at $58.1M in Q1 2018. 2,003 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

  • Boston Advisors held 82,489 shares of AbbVie worth $6.25M as of Q3 2019.
  • Boston Advisors sold 209 AbbVie shares in Q3 2019, an estimated $14.3K.
  • AbbVie made up 0.33% of Boston Advisors's portfolio in Q3 2019, its #84 holding.
  • Boston Advisors first reported a position in AbbVie in Q2 2013 and has held it in 26 quarters since.
  • Boston Advisors's AbbVie position peaked at $58.1M in Q1 2018.
  • 2,003 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.